High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia

Leukemia Research

Volumn 37, Issue 1, 2013, Pages 37-42

  Lou, Yinjun ^a   Qian, Wenbin ^a   Meng, Haitao ^a   Mai, Wenyuan ^a   Tong, Hongyan ^a   Tong, Yin ^a   Huang, Jian ^a   Jin, Jie ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Central nervous system; Relapse

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM METASTASIS; CONSOLIDATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; RETROSPECTIVE STUDIES; TRETINOIN;

EID: 84870941699     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.09.004     Document Type: Article

References (44)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group. Brit J Haematol 1976, 33:451-458.
2. Kakizuka A., Miller W.H., Umesono K., Warrell R.P., Frankel S.R., Murty V.V., et al. Chromosomal translocation t (15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991, 66:663-674.
3. de The H., Lavau C., Marchio A., Chomienne C., Degos L., Dejean A. The PML-RAR alpha fusion mRNA generated by the t (15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991, 66:675-684.
4. Larson R.A., Kondo K., Vardiman J.W., Butler A.E., Golomb H.M., Rowley J.D. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984, 76:827-841.
5. Fenaux P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud E., et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999, 94:1192-1200.
6. Sanz M.A., Martin G., Gonzalez M., Leon A., Rayon C., Rivas C., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004, 103:1237-1243.
7. Mandelli F., Diverio D., Avvisati G., Luciano A., Barbui T., Bernasconi C., et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997, 90:1014-1021.
8. Tallman M.S., Nabhan C., Feusner J.H., Rowe J.M. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002, 99:759-767.
9. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
10. Tallman M.S., Altman J.K. How I treat acute promyelocytic leukemia. Blood 2009, 114:5126-5135.
11. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
12. Park J.H., Tallman M.S. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology (Williston Park) 2011, 25:733-741.
13. Niu C., Yan H., Yu T., Sun H.P., Liu J.X., Li X.S., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
14. Hu J. Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction. Front Med 2011, 5:45-52.
15. Lengfelder E., Hofmann W.K., Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 2012, 26:433-442.
16. Wang H., Chen X.Y., Wang B.S., Rong Z.X., Qi H., Chen H.Z. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leukemia Res 2011, 35:1170-1177.
17. Powell B.L., Moser B., Stock W., Gallagher R.E., Willman C.L., Stone R.M., et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116:3751-3757.
18. Mathews V., George B., Lakshmi K.M., Viswabandya A., Bajel A., Balasubramanian P., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006, 107:2627-2632.
19. Hu J., Liu Y.F., Wu C.F., Xu F., Shen Z.X., Zhu Y.M., et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009, 106:3342-3347.
20. Huang H., Qin Y., Xu R., You X., Teng R., Yang L., et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leukemia Res 2012, 36:841-845.
21. Ravandi F., Estey E., Jones D., Faderl S., O'Brien S., Fiorentino J., et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009, 27:504-510.
22. Mathews V., George B., Chendamarai E., Lakshmi K.M., Desire S., Balasubramanian P., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010, 28:3866-3871.
23. Ghavamzadeh A., Alimoghaddam K., Rostami S., Ghaffari S.H., Jahani M., Iravani M., et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011, 29:2753-2757.
24. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004, 101:5328-5335.
25. Frankel S.R., Eardley A., Lauwers G., Weiss M., Warrell R.P. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Inter Med 1992, 117:292-296.
26. Chen S.J., Chen Z., Chen A., Tong J.H., Dong S., Wang Z.Y., et al. Occurrence of distinct PML-RAR-alpha fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. Oncogene 1992, 7:1223-1232.
27. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
28. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
29. Sanz M.A., Lo Coco F., Martin G., Avvisati G., Rayon C., Barbui T., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96:1247-1253.
30. Park J.H., Qiao B., Panageas K.S., Schymura M.J., Jurcic J.G., Rosenblat T.L., et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011, 118:1248-1254.
31. McClellan J.S., Kohrt H.E., Coutre S., Gotlib J.R., Majeti R., Alizadeh A.A., et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 2012, 97:133-136.
32. de la Serna J., Montesinos P., Vellenga E., Rayon C., Parody R., Leon A., et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008, 111:3395-3402.
33. Vega-Ruiz A., Faderl S., Estrov Z., Pierce S., Cortes J., Kantarjian H., et al. Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol 2009, 89:489-496.
34. Specchia G., Lo Coco F., Vignetti M., Avvisati G., Fazi P., Albano F., et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 2001, 19:4023-4028.
35. de Botton S., Sanz M.A., Chevret S., Dombret H., Martin G., Thomas X., et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006, 20:35-41.
36. Montesinos P., Diaz-Mediavilla J., Deben G., Prates V., Tormo M., Rubio V., et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 2009, 94:1242-1249.
37. Au W.Y., Ma S.K., Ooi C., Liang R., Kwong Y.L. Unusual manifestations of acute leukemia Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission. J Clin Oncol 2000, 18:3435-3437.
38. Mathews V., Balasubramanian P., Shaji R.V., George B., Chandy M., Srivastava A. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide. Brit J Haematol 2001, 113:257-258.
39. Zhang P., Wang S., Hu L., Qiu F., Yang H., Xiao Y., et al. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide - an analysis of 242 cases. Zhonghua Xue Ye Xue Za Zhi 2000, 21:67-70.
40. Gore S.D., Gojo I., Sekeres M.A., Morris L., Devetten M., Jamieson K., et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010, 28:1047-1053.
41. Kiguchi T., Yoshino Y., Yuan B., Yoshizawa S., Kitahara T., Akahane D., et al. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leukemia Res 2010, 34:403-405.
42. Au W.Y., Tam S., Fong B.M., Kwong Y.L. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 2008, 112:3587-3590.
43. Knipp S., Gattermann N., Schapira M., Kaferstein H., Germing U. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leukemia Res 2007, 31:1585-1587.
44. Breccia M., Carmosino I., Diverio D., De Santis S., De Propris M.S., Romano A., et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Brit J Haematol 2003, 120:266-270.